GP2 and metabolic disease: Even though our cross-sectional study did not detect associations of cardiovascular or manifest metabolic disease with higher fecal GP2-levels, elevated systemic inflammation may still increase the risk for cardiovascular disease or negatively affect metabolic conditions such as fatty liver disease or diabetes mellitus in the long-term [41, 42].